Brodalumab: Phase III data

The double-blind, international Phase III AMAGINE-2 trial in >1,800 patients with moderate to severe plaque psoriasis showed that 140 and 210 mg subcutaneous brodalumab every 2 weeks each met the co-primary endpoints of improving PASI 75 response

Read the full 379 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE